Amble Health vs MEDVi vs Yucca Health (2026)

On tirzepatide, the order is Yucca Health↗ ($258) → Amble Health ($300) → MEDVi↗ ($399) — gaps of $42 and then $99 a month, a $1,692 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

Yucca Health: the record, condensed

Start with the load-bearing figure: $258 a month, all-in, is what Yucca Health charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $258 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #2 of 17 in the verified tirzepatide index — $43/month above the floor (NexLife↗, $215) — and sits $191 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,096.

Start with the load-bearing figure: $146 a month, all-in, is what Yucca Health charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #2 of 20 verified programs, with the floor $13/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $203 a month. A year at this figure: $1,752 monthly-billed.

Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗

Amble Health: the record, condensed

Start with the load-bearing figure: $300 a month, all-in, is what Amble Health charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $300 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #9 of 17 in the verified tirzepatide index — $85/month above the floor (NexLife, $215) — and sits $149 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,600.

Operationally at Amble Health: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Amble Health page

MEDVi: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what MEDVi charges for tirzepatide at the 10 mg basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

MEDVi’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

§ The three-way read

Prices, gaps, and what sits inside them

Yucca Health holds the low ground at $258 — dose-flat, so that figure is a ceiling with no membership attached. Amble Health follows at $300 (+$42/mo, $504/yr). MEDVi tops the trio at $399 (+$141/mo over the leader, $1,692/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: Yucca Health $146 → MEDVi $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: Yucca Health ($258); cheapest 12-month path: Yucca Health ($3,096); cheapest semaglutide of the three: Yucca Health ($146).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Yucca Health vs Amble Health (record · record) · Yucca Health vs MEDVi · Amble Health vs MEDVi (record · record).

§ Structure, three ways

Everything besides the three prices

Memberships: Yucca Health none; Amble Health none; MEDVi none. Structures: Yucca Health dose-flat; Amble Health dose-flat; MEDVi dose-flat. Pharmacies: Yucca Health not named; Amble Health not named; MEDVi not named. States: Yucca Health — not published; Amble Health — not published; MEDVi — priced differently in CA/NC on some plans. Exit terms: Yucca Health — 6-month term applies; Amble Health — not published; MEDVi — 12-month plan applies to lowest rate.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Yucca Health source-verified (2026-08-05); Amble Health third-party reported (2026-08-05); MEDVi source-verified (2026-08-05).

The trio on semaglutide, across time

3 mo: Yucca Health $438 vs MEDVi $897 6 mo: Yucca Health $876 vs MEDVi $1,794 12 mo: Yucca Health $1,752 vs MEDVi $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

Yucca Health: $3,096/yr monthly-billed; Amble Health: $3,600/yr monthly-billed; MEDVi: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $3,384 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

Work it as eliminations rather than a beauty contest. MEDVi enters owing an explanation: $141/month above Yucca Health compounds to $1,692 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. Amble Health survives the first cut only to face the harder question — whether nothing structural — its case is purely situational is worth $42 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. Yucca Health is what remains: the arithmetic answer at $258, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.

The same trio on best published rate: Yucca Health $258 → Amble Health $300 → MEDVi $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Yucca Health $774, Amble Health $900, MEDVi $1,197; 6 months — Yucca Health $1,548, Amble Health $1,800, MEDVi $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): Yucca Health 4/5 · Amble Health 3/5 · MEDVi 4/5. The gap between Yucca Health (4/5) and Amble Health (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. No axis splits them, a small collective credit. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.

The three-way verdict compresses cleanly: Yucca Health is the default on arithmetic; Amble Health earns the middle only where its structure (flat pricing) solves something the floor does not; and MEDVi’s $141/month premium over the leader — $1,692 a year, roughly 6.6 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.